Use of sildenafil in patients with severe COVID-19 pneumonitis

Charles McFadyen; Ben Garfield; Jennifer Mancio; Carole A Ridge; Tom Semple; Archie Keeling; Stephane Ledot; Brijesh Patel; Chinthaka B Samaranayake; Colm McCabe; S John Wort; Susanna Price; Laura C Price

doi:10.1016/j.bja.2022.04.004

Use of sildenafil in patients with severe COVID-19 pneumonitis

Br J Anaesth. 2022 Jul;129(1):e18-e21. doi: 10.1016/j.bja.2022.04.004. Epub 2022 Apr 15.

Authors

Affiliations

¹ Adult Intensive Care Unit, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK; Bloomsbury Institute for Intensive Care Medicine, University College London, London, UK. Electronic address: charles.mcfadyen@nhs.net.
² Adult Intensive Care Unit, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
³ Adult Intensive Care Unit, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
⁴ Radiology Department, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
⁵ Adult Intensive Care Unit, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK; Anaesthetics, Pain Medicine & Intensive Care, Surgery & Cancer Division, Imperial College London, London, UK.
⁶ Department of Respiratory Medicine, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
⁷ National Heart and Lung Institute, Imperial College London, London, UK; National Pulmonary Hypertension Service, Royal Brompton Hospital, Guy's & St. Thomas' NHS Foundation Trust, London, UK.

No abstract available

Keywords: COVID-19; acute respiratory distress syndrome; extracorporeal membrane oxygenation; pulmonary hypertension; right ventricular failure; sildenafil.

Publication types

Letter

MeSH terms

COVID-19*
Extracorporeal Membrane Oxygenation* / adverse effects
Humans
Respiratory Distress Syndrome*
Sildenafil Citrate / therapeutic use

Substances

Sildenafil Citrate